Abbott and Enanta Pharmaceuticals announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.
Mylan Inc. said it is launching a generic version of the glaucoma treatment Xalatan after receiving approval from the Food and Drug Administration.
Federal regulators have rejected Pfizer's application for a potentially fatal neurodegenerative disease, said the drugmaker. The Food and Drug Administration called the application for the drug, tafamidis, incomplete.
Orexigen Therapeutics Inc. said information from a late-stage study showed that patients taking its potential diet drug Contrave maintained normal blood pressure patterns around the clock during a year of treatment.
Control Company’s Traceable Ultra-Low Flow Meter is compact, fully contained, ready to operate, no assembly required. Simple 4 button operation (Flow/Total, Units, Zero and Power) and easy to read LCD display make this flow meter extremely user-friendly.
Agilent Automation Solutions has announced accessories for its BioCel System that deliver increased productivity, accessibility, and configuration flexibility.
Thermo Fisher Scientific Inc. announced that its Nicolet iS5 FT-IR spectrometer received a 2011 Scientists' Choice Award for Best New Spectroscopy Product of 2010. The award recognizes the affordable and compact FT-IR spectroscopy capabilities of the instrument.
RXi Pharmaceuticals Corporation and Apthera, Inc. announced the signing of a definitive merger agreement under which RXi will acquire Apthera. The acquisition provides RXi with a late stage product candidate, NeuVax.
New research uses human embryonic stem cells to improve understanding of myotonic dystrophy type 1, and highlights the incredible potential that embryonic stem cells hold for unraveling the complex molecular mechanisms involved in a variety of human conditions.
Researchers have discovered that the obese mice form increased levels of miRNA-143. miRNA-143 inhibits the insulin-stimulated activation of the enzyme AKT. Without active AKT, the blood sugar level is thrown out of kilter.
Biolex Therapeutics, Inc. release the final 72-week results from its SELECT-2 Phase 2b trial of Locteron for the treatment of hepatitis C. Data showed comparable viral response rates to PEG-Intron control and reduced flu-like adverse events and depression.
Polaris Group announced that the U.S. Food & Drug Administration has approved the company’s Special Protocol Assessment for a Phase 3 clinical trial of pegylated arginine deiminase in patients with advanced hepatocellular carcinoma.
Scientists in Finland have revealed metabolic abnormalities that are associated with schizophrenia. This may be an important step towards development of a clinical test of the disease.
Bristol-Myers Squibb Company announced results from a Phase 2 clinical trial in which BMS-790052 in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response in up to 92% of treatment-naïve patients with hepatitis C.
The U. S. Food and Drug Administration approved peginterferon alfa-2b, for the treatment of patients with melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy.